6667 — Mega Genomics Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro Cap

Annual income statement for Mega Genomics, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	203	237	146	151	164
Cost of Revenue
Gross Profit	146	167	81.7	88.3	119
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	91.8	134	166	114	109
Operating Profit	111	103	-20.7	37.3	55.4
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	94.9	95.9	-21.4	36.2	53.6
Provision for Income Taxes
Net Income After Taxes	79.1	79	-17.6	30	45
Net Income Before Extraordinary Items
Net Income	79.1	79	-17.6	30	45
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	79.1	79	-17.6	30	45
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.331	0.398	-0.037	0.142	0.217